Turing’s Shkreli Tussels With Express Scripts About ‘Ugly, Dirty Truth’ Of Drug Pricing
This article was originally published in The Pink Sheet Daily
Martin Shkreli says he will not lower price of antiparasitic Daraprim, noting shareholders want firm to make as much money as possible; he thanks Express Scripts’ CMO for not excluding the drug.
You may also be interested in...
The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.
Guidance on compounding commercially available drugs states that prescribers can order them as long as there's a clinical difference for the patient – a standard that likely helps Daraprim but not Lucentis.
Pharmacy benefit manager's anti-Daraprim effort signals new direction in pricing battles, but the strategy can only be used in limited circumstances.